AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17429784 — intervention group
Group type: EXPERIMENTAL
Intervention: Compact extracorporeal circulation (ECC)
Number of subjects: 0
Study 15553551 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based small-group education for children and home-based education for parents
Number of subjects: 44
Study 15553551 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 44
Study 11245349 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous oral vitamin E supplementation for 6 weeks
Number of subjects: 0
Study 11245349 — intervention group
Group type: COMPARATOR
Intervention: Control PEM subjects
Number of subjects: 0
Study 9575674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of local anesthetic
Number of subjects: 1
Study 9575674 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 1
Study 8638785 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain management with continuous epidural bupivacaine (S‐E group, n = 15)
Number of subjects: 30
Study 8638785 — intervention group
Group type: COMPARATOR
Intervention: Control group without epidural bupivacaine (S group, n = 15)
Number of subjects: 30
Study 2405034 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial prebrushing mouthrinse and brushing with a dentifrice for 30 seconds
Number of subjects: 51
Study 2405034 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebrushing water rinse and brushing with a dentifrice for 30 seconds
Number of subjects: 51
Study 2405034 — intervention group
Group type: COMPARATOR
Intervention: No toothbrushing
Number of subjects: 51
Study 2405034 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial prebrushing mouthrinse
Number of subjects: 51
Study 2405034 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebrushing water rinse
Number of subjects: 51
Study 6986968 — intervention group
Group type: EXPERIMENTAL
Intervention: FC‐CCNU (5‐FU, Cyclophosphamide, CCNU)
Number of subjects: 47
Study 6986968 — intervention group
Group type: COMPARATOR
Intervention: FC‐MTX (5‐FU, Cyclophosphamide, Methotrexate)
Number of subjects: 47
Study 6986968 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 47
Study 31282555 — intervention group
Group type: EXPERIMENTAL
Intervention: Papworth method relaxation training
Number of subjects: 30
Study 28253887 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (3 times per week for 5 weeks, maximum of 45 minutes walking time each)
Number of subjects: 0
Study 28253887 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (1-2 sessions of physiotherapy per week, hippotherapy, circuit training, and occupational therapy as necessary for 5 weeks)
Number of subjects: 0
Study 26589253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 444
Study 26589253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 444
Study 26589253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 444
Study 24758776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal lidocaine 50 mg/h (10 ml) once every hour
Number of subjects: 60
Study 24758776 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of lidocaine 50 mg/h (10 ml) IV
Number of subjects: 60
Study 24758776 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline 10 ml/h both intravenously and intermittently intraperitoneal
Number of subjects: 60
Study 22717420 — intervention group
Group type: EXPERIMENTAL
Intervention: T80/H25 SPC (telmisartan/hydrochlorothiazide 80/25 mg)
Number of subjects: 894
Study 22717420 — intervention group
Group type: COMPARATOR
Intervention: T80 (telmisartan 40 mg)
Number of subjects: 894
Study 20151774 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5 microg twice a day (titrated to 10 microg twice a day)
Number of subjects: 128
Study 20151774 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide 2.5 mg three times a day (titrated to 5 mg three times a day)
Number of subjects: 128
Study 18082876 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilingual Product Information Labels (PILs)
Number of subjects: 225
Study 18082876 — intervention group
Group type: COMPARATOR
Intervention: Old label format
Number of subjects: 225
Study 18082876 — intervention group
Group type: COMPARATOR
Intervention: New label format
Number of subjects: 225
Study 18082876 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish only consumers with PILs
Number of subjects: 225
Study 16230141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal 100‐mg diclofenac suppository 1 hour before biopsy
Number of subjects: 40
Study 16230141 — intervention group
Group type: COMPARATOR
Intervention: Glycerin suppository as placebo intrarectally 1 hour before biopsy
Number of subjects: 40
Study 12399191 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg/AS04 vaccine
Number of subjects: 115
Study 12399191 — intervention group
Group type: COMPARATOR
Intervention: Established hepatitis B vaccine
Number of subjects: 115
Study 9144119 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial whey hydrolysate formula
Number of subjects: 216
Study 9144119 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding for > or = 4 months
Number of subjects: 216
Study 9144119 — intervention group
Group type: COMPARATOR
Intervention: Conventional cow's milk formula
Number of subjects: 216
Study 9144119 — intervention group
Group type: COMPARATOR
Intervention: Soy formula
Number of subjects: 216
Study 9144119 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey hydrolysate formula
Number of subjects: 216
Study 9144119 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding and whey hydrolysate
Number of subjects: 216
Study 9144119 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey hydrolysate
Number of subjects: 216
Study 8431329 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil
Number of subjects: 100
Study 8431329 — intervention group
Group type: COMPARATOR
Intervention: suxamethonium
Number of subjects: 100
Study 3315604 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 90
Study 3315604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 29641834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride
Number of subjects: 248
Study 29641834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 29641834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rACC theta marker with clinical and demographic variables
Number of subjects: 248
Study 26822100 — intervention group
Group type: EXPERIMENTAL
Intervention: K305 (3% tetracaine plus 0.05% oxymetazoline)
Number of subjects: 150
Study 26822100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 24880442 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanins from grapes
Number of subjects: 52
Study 24880442 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate-neomycin-nystatin cream (CP-NN)
Number of subjects: 52
Study 22268727 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA reconstituted with preserved saline
Number of subjects: 20
Study 22268727 — intervention group
Group type: COMPARATOR
Intervention: AbobotulinumtoxinA reconstituted with preservative-free saline
Number of subjects: 20
Study 20379742 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic reminder system for pathologists and education for surgeons; pathologists received inclusion criteria cards and feedback on inclusion.
Number of subjects: 266
Study 20379742 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic reminder system for pathologists.
Number of subjects: 266
Study 17918748 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulation treatment
Number of subjects: 51
Study 17918748 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking on SFEMG
Number of subjects: 51
Study 15855433 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand-specific request
Number of subjects: 152
Study 15855433 — intervention group
Group type: EXPERIMENTAL
Intervention: General request
Number of subjects: 152
Study 15855433 — intervention group
Group type: COMPARATOR
Intervention: No request (control)
Number of subjects: 152
Study 12486923 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical removal of ICH
Number of subjects: 668
Study 12486923 — intervention group
Group type: COMPARATOR
Intervention: Initial conservative management
Number of subjects: 668
Study 10353863 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 32
Study 10353863 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 32
Study 10353863 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 32
Study 7574449 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Zero Method (RM)
Number of subjects: 58
Study 7574449 — intervention group
Group type: COMPARATOR
Intervention: Original Method (OM)
Number of subjects: 58
Study 2057620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular premedication with 0.2 mg/kg of midazolam and 0.015 mg/kg of atropine
Number of subjects: 40
Study 2057620 — intervention group
Group type: COMPARATOR
Intervention: Intranasal premedication with 0.2 mg/kg of midazolam and 0.015 mg/kg of atropine
Number of subjects: 40
Study 2057620 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Intramuscular and Intranasal)
Number of subjects: 40
Study 6343360 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 60
Study 6343360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6343360 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 60
Study 30302744 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation intervention
Number of subjects: 344
Study 29574482 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 36
Study 29574482 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training combined with intravaginal electrical stimulation (PFMT+IVES)
Number of subjects: 36
Study 27292282 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed apixaban tablets in 30 mL of water
Number of subjects: 55
Study 27292282 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed apixaban tablets in applesauce
Number of subjects: 55
Study 27292282 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole apixaban tablets with a high-fat, high-calorie meal
Number of subjects: 55
Study 27292282 — intervention group
Group type: COMPARATOR
Intervention: Whole apixaban tablets fasted (reference)
Number of subjects: 55
Study 24613032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vabicaserin 200 mg/day
Number of subjects: 314
Study 24613032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vabicaserin 400 mg/day
Number of subjects: 314
Study 24613032 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg/day
Number of subjects: 314
Study 24613032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 22102736 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 plus cisplatin (2 courses)
Number of subjects: 120
Study 22102736 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 plus cisplatin (4 courses)
Number of subjects: 120
Study 22102736 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 plus cisplatin plus docetaxel (2 courses)
Number of subjects: 120
Study 22102736 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 plus cisplatin plus docetaxel (4 courses)
Number of subjects: 120
Study 20519076 — intervention group
Group type: EXPERIMENTAL
Intervention: Depsides salts from salvia miltiorrhiza (DSM) 0.2 g intravenously daily for 2 weeks
Number of subjects: 40
Study 20519076 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT)
Number of subjects: 40
Study 20519076 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy adults)
Number of subjects: 40
Study 17173661 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b (1.5 microg/kg/week) with ribavirin (800-1000 mg daily) for 48 weeks for genotype 1 and 4, 24 weeks for other genotypes
Number of subjects: 27
Study 17173661 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b with ribavirin
Number of subjects: 27
Study 17173661 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 27
Study 15792278 — intervention group
Group type: EXPERIMENTAL
Intervention: Recorded delivery
Number of subjects: 699
Study 15792278 — intervention group
Group type: COMPARATOR
Intervention: Standard delivery
Number of subjects: 699
Study 15792278 — intervention group
Group type: EXPERIMENTAL
Intervention: Stamped return envelops
Number of subjects: 699
Study 15792278 — intervention group
Group type: COMPARATOR
Intervention: Franked return envelops
Number of subjects: 699
Study 12515052 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAGNOdent (DD)
Number of subjects: 97
Study 12515052 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitewing radiographs (BW)
Number of subjects: 97
Study 12515052 — intervention group
Group type: COMPARATOR
Intervention: Visual-ranked inspection (VI)
Number of subjects: 97
Study 9875065 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed diets containing different amounts and types of fibre
Number of subjects: 0
Study 9875065 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus fibre concentrate
Number of subjects: 0
Study 9875065 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse wholemeal rye bread
Number of subjects: 0
Study 9875065 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine wholemeal rye bread
Number of subjects: 0
Study 9875065 — intervention group
Group type: COMPARATOR
Intervention: In vitro fermentation of mixed diets and citrus fibre concentrate
Number of subjects: 0
Study 9875065 — intervention group
Group type: COMPARATOR
Intervention: In vitro fermentation of wholemeal rye breads
Number of subjects: 0
Study 7897074 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Examination Facilitation Device (BEFD) made of latex, paper, or cloth with a wedge pattern for BSE
Number of subjects: 36
Study 7897074 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Examination Facilitation Device (BEFD)
Number of subjects: 36
Study 2706173 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection at L2/3 with 3 ml of plain 0.5% bupivacaine
Number of subjects: 40
Study 2706173 — intervention group
Group type: COMPARATOR
Intervention: Injection at L4/5 with 3 ml of plain 0.5% bupivacaine
Number of subjects: 40
Study 351355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine (4 mg/70 kg)
Number of subjects: 13
Study 351355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg)
Number of subjects: 13
Study 31925917 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulsed Nd:YAG 1064-nm laser treatment
Number of subjects: 60
Study 31925917 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical amorolfine nail lacquer alone
Number of subjects: 60
Study 31925917 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (laser + amorolfine)
Number of subjects: 60
Study 30772850 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) intervention
Number of subjects: 152
Study 30772850 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 152
Study 28873425 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor residual spraying (IRS) with alpha cypermethrin 5WP
Number of subjects: 3089
Study 28873425 — intervention group
Group type: EXPERIMENTAL
Intervention: Long lasting insecticide impregnated bed-net (LLIN)
Number of subjects: 3089
Study 28873425 — intervention group
Group type: EXPERIMENTAL
Intervention: Impregnation of local bed-nets with slow release insecticide K-O TAB 1-2-3 (KOTAB)
Number of subjects: 3089
Study 28873425 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide spraying in potential breeding sites outside of house using chlorpyrifos 20EC (OUT)
Number of subjects: 3089
Study 28873425 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IRS and OUT
Number of subjects: 3089
Study 28873425 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IRS and LLIN
Number of subjects: 3089
Study 28873425 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IRS and KOTAB
Number of subjects: 3089
Study 28873425 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 3089
Study 25502833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVI) 0.5 mg with isovolemic hemodilution (IH)
Number of subjects: 58
Study 25502833 — intervention group
Group type: COMPARATOR
Intervention: Isovolemic hemodilution (IH) alone
Number of subjects: 58
Study 21815991 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth neck implant
Number of subjects: 93
Study 21815991 — intervention group
Group type: EXPERIMENTAL
Intervention: Rough neck implant with grooves
Number of subjects: 93
Study 21815991 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalloped rough neck with grooves
Number of subjects: 93
Study 21815991 — intervention group
Group type: COMPARATOR
Intervention: Pre-implant augmentation procedure
Number of subjects: 93
Study 21261621 — intervention group
Group type: EXPERIMENTAL
Intervention: DFDBA + omega‐3 polyunsaturated fatty acids + low‐dose aspirin
Number of subjects: 40
Study 21261621 — intervention group
Group type: COMPARATOR
Intervention: DFDBA + placebo
Number of subjects: 40
Study 19021072 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian Indian adolescents
Number of subjects: 780
Study 19021072 — intervention group
Group type: COMPARATOR
Intervention: Controls (Guadeloupeans not originating from India)
Number of subjects: 780
Study 15979109 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured or unstructured spatial arrays
Number of subjects: 0
Study 15979109 — intervention group
Group type: COMPARATOR
Intervention: Control group (closely matched controls)
Number of subjects: 0
Study 12772755 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses
Number of subjects: 658
Study 11106141 — intervention group
Group type: EXPERIMENTAL
Intervention: Gotu Kola (12-g orally administered dose)
Number of subjects: 40
Study 11106141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9377067 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvolume fluorimetry (MVF) method for CD34+ cell enumeration
Number of subjects: 0
Study 8404786 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea fibre
Number of subjects: 6
Study 8404786 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean fibre
Number of subjects: 6
Study 8404786 — intervention group
Group type: COMPARATOR
Intervention: Low-fibre test meal (control)
Number of subjects: 6
Study 2877708 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12
Study 2877708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31892657 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioural intervention including playing Tetris
Number of subjects: 144
Study 31892657 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo control group completing a brief written activity log
Number of subjects: 144
Study 31892657 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (Tetris)
Number of subjects: 144
Study 31892657 — intervention group
Group type: COMPARATOR
Intervention: Control group (activity log)
Number of subjects: 144
Study 31892657 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 144
Study 30409131 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose dexmedetomidine (1.0 μg/kg loading followed by 0.5 μg/kg/min infusion)
Number of subjects: 75
Study 30409131 — intervention group
Group type: EXPERIMENTAL
Intervention: Half dose dexmedetomidine (0.5 μg/kg loading followed by 0.25 μg/kg/min infusion)
Number of subjects: 75
Study 30409131 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 75
Study 26676193 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% white vinegar
Number of subjects: 60
Study 26676193 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium hypochlorite (NaOCl)
Number of subjects: 60
Study 26676193 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse containing essential oils and alcohol
Number of subjects: 60
Study 26676193 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate
Number of subjects: 60
Study 26676193 — intervention group
Group type: EXPERIMENTAL
Intervention: Dishwasher use
Number of subjects: 60
Study 26676193 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 60
Study 25073447 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led brief motivational intervention (BMI)
Number of subjects: 238
Study 22266642 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted vest intervention (3 d·wk for 3 weeks during waking hours)
Number of subjects: 17
Study 22266642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no weighted vest)
Number of subjects: 17
Study 22266642 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted vest intervention
Number of subjects: 17
Study 22266642 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study 20818904 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant platinum‐based chemotherapy followed by interval debulking surgery
Number of subjects: 670
Study 20818904 — intervention group
Group type: COMPARATOR
Intervention: Primary debulking surgery followed by platinum‐based chemotherapy
Number of subjects: 670
Study 19000553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg, 8 mg, or 12 mg sustained-release tablets
Number of subjects: 24
Study 19000553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg in fed state
Number of subjects: 24
Study 19000553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine at all doses
Number of subjects: 24
Study 19000553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine in PMs
Number of subjects: 24
Study 19000553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Number of subjects: 24
Study 16308008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen, 2.4 atmospheres absolute
Number of subjects: 64